13F Holdings
中文EN

BOLD Boundless Bio, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1782303 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY10.1%
TTM EPS YoY7.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-64.6%
ROA-47.8%
ROIC (approx.)-76.5%
Asset turnover—

Leverage & solvency

Liabilities / assets2.9%
Debt / equity0.00x
Current ratio33.97x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.03x
Accruals ratio1.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$1.44M$13.97M$9.73M$9.82M$10.67M$12.22M$12.14M$13.31M
SG&A expense$4.76M$10.41M$4.74M$4.18M$4.47M$4.84M$5.20M$4.96M
Operating income-$6.20M-$24.38M-$14.47M-$14.00M-$15.15M-$17.06M-$17.34M-$18.28M
Net income-$5.36M-$23.69M-$13.55M-$12.88M-$13.88M-$15.68M-$15.76M-$16.45M
EBITDA-$6.10M-$23.08M-$14.19M-$13.70M-$14.85M-$16.76M-$17.02M-$17.98M
EPS (basic)-0.23-1.06-0.60—-0.62-0.70-0.71—
EPS (diluted)-0.23-1.06-0.60—-0.62-0.70-0.71—
Weighted avg. shares (diluted)22.86M22.45M22.41M—22.39M22.36M22.30M—
Balance sheet
Cash & equivalents$34.91M$20.21M$17.48M$17.87M$14.98M$14.70M$15.12M$27.15M
Short-term investments$27.98M$52.41M$75.36M$89.71M$102.59M$112.45M$123.14M$125.53M
Current assets$63.59M$73.65M$94.62M$109.61M$120.16M$129.69M$140.36M$154.39M
PP&E, net$0$97,000$2.94M$3.22M$3.50M$3.79M$4.08M$4.32M
Total assets$63.59M$73.74M$140.97M$157.06M$168.72M$179.45M$191.24M$206.41M
Current liabilities$1.87M$7.77M$9.58M$12.54M$11.85M$9.21M$6.34M$8.13M
Total liabilities$1.87M$7.77M$54.59M$58.41M$58.55M$56.76M$54.65M$55.77M
Shareholders' equity$61.72M$65.98M$86.38M$98.65M$110.17M$122.69M$136.59M$150.64M
Shares outstanding23.11M22.48M22.41M22.41M22.39M22.39M22.30M22.30M
Cash flow statement
Operating cash flow-$10.88M-$20.97M-$14.97M-$10.11M-$10.20M-$11.83M-$14.53M-$15.56M
Capital expenditure$0$38,000$8,000$424,000$15,000$48,000$59,000$466,000
Free cash flow-$10.88M-$21.01M-$14.98M-$10.53M-$10.21M-$11.88M-$14.59M-$16.03M
Investing cash flow$24.77M$23.07M$14.59M$12.97M$10.48M$11.29M$3.06M$1.82M
Financing cash flow$813,000——$24,000$0——$113,000
Depreciation & amortization$100,000$1.30M$284,000$307,000$300,000$300,000$317,000$296,000
Stock-based compensation$284,000$3.22M$1.37M$1.33M$1.30M$1.69M$1.80M$2.01M

Free plan shows the latest 8 periods; Pro shows all 15 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.